A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Completed · Phase 2 · Has a placebo group

Conditions studied: Plaque Psoriasis

In brief

The main purpose of this study is to determine the efficacy and safety of LY3972406 in adult participants with moderate-to-severe plaque psoriasis.

Key facts

Study ID

NCT06176768

Run by

Eli Lilly and Company

People needed

33

Starts

2023-12-06

Expected to finish

2025-05-06

Last updated by the study team

2025-10-15

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have moderate-to-severe chronic plaque psoriasis for at least 6 months prior to baseline
• Have venous access sufficient to allow for blood sampling
• Are able to swallow oral medication

You may not qualify if…

• Have any other skin conditions, excluding plaque psoriasis
• Have a current or recent acute, active infection
• Have manifestations of other autoimmune diseases, such as systemic lupus erythematosus.
• Are lactating or breastfeeding women

Where it is running

• Dermatology Research Associates — Los Angeles, California, United States
• Clinical Science Institute — Santa Monica, California, United States
• Driven Research — Coral Gables, Florida, United States
• Conquest Research — Winter Park, Florida, United States
• Psoriasis Treatment Center of Central New Jersey — East Windsor, New Jersey, United States
• Schweiger Dermatology Group — Hackensack, New Jersey, United States
• Metropolitan Dermatology - Clark — Kenilworth, New Jersey, United States
• Accellacare - Winston-Salem — Winston-Salem, North Carolina, United States
• Remington-Davis, Inc — Columbus, Ohio, United States
• DermDox Centers for Dermatology — Camp Hill, Pennsylvania, United States
• Center for Clinical Studies — Houston, Texas, United States
• Austin Institute for Clinical Research — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.